Dipeptidyl Peptidase IV in Inflammatory Bowel Diseases (DPP IV/CD26)

Pučar, Lara Batičić; Detel, Dijana; Varljen, Jadranka

doi:10.2478/10004-1254-63-2012-2185

Cited by 2 publications

(3 citation statements)

References 148 publications

(156 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding a catalytic function of DPP-4 on GLP-1 and GLP-2, previous studies have demonstrated that DPP-4 can act as an immune regulator via its expression on immune cells and the ability to cleave biologically active chemokines and cytokines. Hence, DPP-4 involvement in the pathogenesis of colitis has been proposed ( 96 ). The involvement of DPP-4 might depend on two major pathways: the catalytic function and non-catalytic function ( 38 , 73 , 97 ).…”

Section: Inhibition Of Dpp-4 Function In Ibdmentioning

confidence: 99%

Role of Incretin Axis in Inflammatory Bowel Disease

et al. 2017

View full text Add to dashboard Cite

The inflammatory bowel diseases (IBDs), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic inflammatory conditions of the gastrointestinal tract and involve a complicated reciprocity of environmental, genetic, and immunologic factors. Despite substantial advances in the foundational understanding of the immunological pathogenesis of IBD, the detailed mechanism of the pathological progression in IBD remains unknown. In addition to Th1/Th2 cells, whose role in IBD has been previously well defined, recent evidence indicates that Th17 cells and Tregs also play a crucial role in the development of IBD. Diets which contain excess sugars, salt, and fat may also be important actors in the pathogenesis of IBD, which may be the cause of high IBD incidence in western developed and industrialized countries. Up until now, the reason for the variance in prevalence of IBD between developed and developing countries has been unknown. This is partly due to the increasing popularity of western diets in developing countries, which makes the data harder to interpret. The enterocrinins glucagon-like peptides (GLPs), including GLP-1 and GLP-2, exhibit notable benefits on lipid metabolism, atherosclerosis formation, plasma glucose levels, and maintenance of gastric mucosa integrity. In addition to the regulation of nutrient metabolism, the emerging role of GLPs and their degrading enzyme dipeptidyl peptidase-4 (DPP-4) in gastrointestinal diseases has gained increasing attention. Therefore, here we review the function of the DPP-4/GLP axis in IBD.

show abstract

Section: Inhibition Of Dpp-4 Function In Ibdmentioning

confidence: 99%

Role of Incretin Axis in Inflammatory Bowel Disease

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The inhibition of all of the above mentioned enzymes by peptides is associated with a positive impact on cardiovascular health and reduction of high blood pressure [ 19 , 48 , 49 ]. However, ACE-I, renin, DPP-IV and PAF-AH are enzymes that are also present in the gut, and recent evidence suggests that inhibition of these enzymes can impact positively on gut health and may help to prevent necrosis, ulcerative colitis and other inflammatory disorders of the human gut [ 8 , 9 , 13 , 17 ].…”

Section: Discussionmentioning

confidence: 99%

“…Inhibition of the enzymes ACE-I, renin, PAF-AH and DPP-IV is known to lower systemic and local blood pressure, and assist in the alleviation of symptoms of several disorders including diabetes mellitus [ 7 ], hypercholesterolaemia, inflammatory diseases [ 8 , 9 ], and fibrosis [ 10 ]. Inhibition of ACE-I prevents the formation of angiotensin II, a potent vasoconstrictor while renin inhibition prevents the formation of angiotensin I, the precursor of angiotensin II [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Gastrointestinal Endogenous Protein-Derived Bioactive Peptides: An in Vitro Study of Their Gut Modulatory Potential

Dave

Hayes

Mora

et al. 2016

IJMS

View full text Add to dashboard Cite

A recently proposed paradigm suggests that, like their dietary counterparts, digestion of gastrointestinal endogenous proteins (GEP) may also produce bioactive peptides. With an aim to test this hypothesis, in vitro digests of four GEP namely; trypsin (TRYP), lysozyme (LYS), mucin (MUC), serum albumin (SA) and a dietary protein chicken albumin (CA) were screened for their angiotensin-I converting (ACE-I), renin, platelet-activating factor-acetylhydrolase (PAF-AH) and dipeptidyl peptidase-IV inhibitory (DPP-IV) and antioxidant potential following simulated in vitro gastrointestinal digestion. Further, the resultant small intestinal digests were enriched to obtain peptides between 3–10 kDa in size. All in vitro digests of the four GEP were found to inhibit ACE-I compared to the positive control captopril when assayed at a concentration of 1 mg/mL, while the LYS < 3-kDa permeate fraction inhibited renin by 40% (±1.79%). The LYS < 10-kDa fraction inhibited PAF-AH by 39% (±4.34%), and the SA < 3-kDa fraction inhibited DPP-IV by 45% (±1.24%). The MUC < 3-kDa fraction had an ABTS-inhibition antioxidant activity of 150 (±24.79) µM trolox equivalent and the LYS < 10-kDa fraction inhibited 2,2-Diphenyl-1-picrylhydrazyl (DPPH) by 54% (±1.62%). Moreover, over 190 peptide-sequences were identified from the bioactive GEP fractions. The findings of the present study indicate that GEP are a significant source of bioactive peptides which may influence gut function.

show abstract

Dipeptidyl Peptidase IV in Inflammatory Bowel Diseases (DPP IV/CD26)

Cited by 2 publications

References 148 publications

Role of Incretin Axis in Inflammatory Bowel Disease

Role of Incretin Axis in Inflammatory Bowel Disease

Gastrointestinal Endogenous Protein-Derived Bioactive Peptides: An in Vitro Study of Their Gut Modulatory Potential

Contact Info

Product

Resources

About